** Shares of drugmaker Vanda Pharmaceuticals fall 10.9% to $4.41 premarket

** Co says U.S. FDA declined to approve its stomach paralysis drug, tradipitant

** Co says the FDA suggested that Vanda conduct additional studies

** Will continue to pursue approval for the drug to treat gastroparesis, characterized by delayed gastric emptying

** Plans to submit separate marketing application for tradipitant to prevent vomiting during motion sickness later this year

** Stock up 17.3% YTD vs 11.3% rise in the Nasdaq Biotechnology Index

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))